DrugPatentWatch Database Preview
Details for Patent: 8,309,122
» See Plans and Pricing
Which drugs does patent 8,309,122 protect, and when does it expire?
Patent 8,309,122 protects OPANA ER and is included in one NDA.
This patent has forty-eight patent family members in sixteen countries.
Summary for Patent: 8,309,122
Title: | Oxymorphone controlled release formulations |
Abstract: | The invention pertains to a method of relieving pain by administering a controlled release pharmaceutical tablet containing oxymorphone which produces a mean minimum blood plasma level 12 to 24 hours after dosing, as well as the tablet producing the sustained pain relief. |
Inventor(s): | Kao; Huai-Hung (Syosset, NY), Baichwal; Anand R. (Wappingers Falls, NY), McCall; Troy (Smyma, GA), Lee; David (Chadds Ford, PA) |
Assignee: | Endo Pharmaceuticals Inc. (Chadds Ford, PA) |
Application Number: | 11/680,432 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,309,122 |
Patent Claim Types: see list of patent claims | Composition; Formulation; Dosage form; Delivery; Use; |
Drugs Protected by US Patent 8,309,122
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Endo Pharms | OPANA ER | oxymorphone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 201655-001 | Dec 9, 2011 | DISCN | Yes | No | Start Trial | Start Trial | Y | Start Trial | ||||
Endo Pharms | OPANA ER | oxymorphone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 201655-002 | Dec 9, 2011 | DISCN | Yes | No | Start Trial | Start Trial | Y | Start Trial | ||||
Endo Pharms | OPANA ER | oxymorphone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 201655-003 | Dec 9, 2011 | DISCN | Yes | No | Start Trial | Start Trial | Y | Start Trial | ||||
Endo Pharms | OPANA ER | oxymorphone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 201655-004 | Dec 9, 2011 | DISCN | Yes | No | Start Trial | Start Trial | Y | Start Trial | ||||
Endo Pharms | OPANA ER | oxymorphone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 201655-005 | Dec 9, 2011 | DISCN | Yes | No | Start Trial | Start Trial | Y | Start Trial | ||||
Endo Pharms | OPANA ER | oxymorphone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 201655-006 | Dec 9, 2011 | DISCN | Yes | No | Start Trial | Start Trial | Y | Start Trial | ||||
Endo Pharms | OPANA ER | oxymorphone hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 201655-007 | Dec 9, 2011 | DISCN | Yes | No | Start Trial | Start Trial | Y | Start Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,309,122
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Austria | 359077 | Start Trial | |||
Austria | 376832 | Start Trial | |||
Australia | 2002316582 | Start Trial | |||
Australia | 2002318211 | Start Trial | |||
Australia | 2002320309 | Start Trial | |||
Brazil | 0205721 | Start Trial | |||
Brazil | 0205722 | Start Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |